Author/Editor		Debevec, Lučka
Title		Vpliv spremljajočih bolezni na preživetje bolnikov s pljučnim rakom
Translated title		Influence og comorbidity on the survival of patients with lung cancer
Type		članek
Source		Zdrav Vestn
Vol. and No.		Letnik 76, št. 2
Publication year		2007
Volume		str. 81-5
Language		slo
Abstract		The aim oft hestudy was to establish the comorbidity in the presented group of lung cancer patients and to examine the applicability of CI by determining the difference of survival rate according to CI In 259 non-small cell lung cancer patients, median age 65, primarily treated nonsurgicahy (radiotherapy 187, radio- and chemotherapy 6 radiotherapy and interferon 3, chemotherapy 2, simptomatically 27, unknown 34), clinical stage IA in 9, IB in 51, IIA in 1, IIB in 61, IIIA in 116 IIIB in 14 and lV in 7 patients, the comorbidity and the survival rate according to CI were established. No comorbidity was established in 66 (25.5% of patients, CI 1 in 121 (46,7%), C1 2 in 54 (29.8 %), CI 3 in 14 (5.4%), CI 4 in 3 (1.2%), and CI 5 in 1 (0.4%) patient. The majority (146 patients) had pulmonary disease, followed by cardiovascular disease (40 patients), other conditions were rarely observed. Median survival of CI O patients was 13.3 months, CI 1 patients 11,1 months, CI 2-5 patients 9.9 months. The survival difference was statistically significant (p = 0.035Z). Most of the lung cancer patients had also other pulmonary and cardiovascular diseases. The survival rate was significantly different according to the established CI This way the usefulness of Cl for determining the comorbidity in non-small cell lung cancer patients was confirmed.
Summary		Klinični stadij telesna zmogljivost in komorbidnost odločilno vplivajo na način zdravljenja in napoved izida pri raku. Namen raziskave je ugotoviti pri naših holnikih s pljučnim rakom spremljajoče bolezni in razliko v preživetju glede na indeks komorbidnosti Charlsonove (CI) ter s tem preveriti uporabncst CI za ugotavljanje vpliva spremljajočih bolezni na prežive je. Pri 259 bolnikila z nedrobnoceličnim rakom pljuč srednje starosti 65 let, primarno zdravljenih neoperativno (z obsevanjem 187, z obsevanjem in kemoterapijo 6 z obsevanjem in interferonom 3, s kemoterapijo 2, simptomatsko 27, nepoznano preostalih 34), s kliničnim stadijem IA pri 9, IB pri 51, IIA pri 1, IIB pri 61, IIIA pri 116, IIIB pri 14 in IV pri 7, smo ugotavljali spremljajoče bolezni in primerjali preživetje glede na CI. Spremljajočih bolezni ni imelo 66 (25,5% bolnikov, CI 1 je imelo 121 (46,7%), CI 2 54 (29,8 %), CI 3 14 (5,4%) CI 4 3 (1,2%) in CI 5 1 (0 4%) bolnik. Največ (146) bolnikov je imelo pljučno bolezen, sledijo bolezni srca in ožilja pri 40 bolnikih, druge bolezni so bile redkejše. Srednje prežive je boluikov s CI 0 je bilo 13,3 meseca s CI 1 11,1 in s CI 2 ali več pa 9,9. Razlika je statistično značilna (p = 0, 035Z). Največ bolnikov s pljučnim rakom je imelo še druge bolezni pljuč srca in ožilja. Preživetje glede na ugotovljeni Cl je bilo značilno različno in s tem potrjena ustreznost Cl za ocenjevanje vpliva spremljajočih bolezni pri bolnikih z nedrobnoceličuim pljučnim rakom.
Descriptors		LUNG NEOPLASMS COMORBIDITY SURVIVAL ANALYSIS